Imipenem: a new carbapenem antibiotic. 1988

B Lipman, and H C Neu
Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, New York.

Imipenem is a new carbapenem antibiotic that has an extremely broad spectrum of antibacterial activity. It has been used to treat a variety of serious infections and an increasing volume of literature documents its value in infections due to multiresistant bacteria. This article reviews the antibacterial activity, pharmacology, and clinical uses of imipenem.

UI MeSH Term Description Entries
D003521 Cyclopropanes Three-carbon cycloparaffin cyclopropane (the structural formula (CH2)3) and its derivatives.
D004338 Drug Combinations Single preparations containing two or more active agents, for the purpose of their concurrent administration as a fixed dose mixture. Drug Combination,Combination, Drug,Combinations, Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077728 Cilastatin, Imipenem Drug Combination Combination of imipenem and cilastatin that is used in the treatment of bacterial infections; cilastatin inhibits renal dehydropeptidase I to prolong the half-life and increase the tissue penetration of imipenem, enhancing its efficacy as an anti-bacterial agent. Imipenem - Cilastatin,Imipenem - Cilastatin Sodium,Imipenem Cilastatin,Imipenem Cilastatin Sodium,Imipenem-Cilastatin,Imipenem-Cilastatin Sodium,Imipenem-Cilastatin, Sodium Salt,MK 0787-MK 0791 mixture,MK 787-MK 791 mixture,Primaxin,Thienam,Tienam 500,Zienam,Cilastatin, Imipenem,Imipenem Cilastatin, Sodium Salt,MK 0787 MK 0791 mixture,MK 787 MK 791 mixture
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000900 Anti-Bacterial Agents Substances that inhibit the growth or reproduction of BACTERIA. Anti-Bacterial Agent,Anti-Bacterial Compound,Anti-Mycobacterial Agent,Antibacterial Agent,Antibiotics,Antimycobacterial Agent,Bacteriocidal Agent,Bacteriocide,Anti-Bacterial Compounds,Anti-Mycobacterial Agents,Antibacterial Agents,Antibiotic,Antimycobacterial Agents,Bacteriocidal Agents,Bacteriocides,Agent, Anti-Bacterial,Agent, Anti-Mycobacterial,Agent, Antibacterial,Agent, Antimycobacterial,Agent, Bacteriocidal,Agents, Anti-Bacterial,Agents, Anti-Mycobacterial,Agents, Antibacterial,Agents, Antimycobacterial,Agents, Bacteriocidal,Anti Bacterial Agent,Anti Bacterial Agents,Anti Bacterial Compound,Anti Bacterial Compounds,Anti Mycobacterial Agent,Anti Mycobacterial Agents,Compound, Anti-Bacterial,Compounds, Anti-Bacterial
D001424 Bacterial Infections Infections by bacteria, general or unspecified. Bacterial Disease,Bacterial Infection,Infection, Bacterial,Infections, Bacterial,Bacterial Diseases
D013845 Thienamycins Beta-lactam antibiotics that differ from PENICILLINS in having the thiazolidine sulfur atom replaced by carbon, the sulfur then becoming the first atom in the side chain. They are unstable chemically, but have a very broad antibacterial spectrum. Thienamycin and its more stable derivatives are proposed for use in combinations with enzyme inhibitors. Antibiotics, Thienamycin,Thienamycin Antibiotics
D015377 Cilastatin A renal dehydropeptidase-I and leukotriene D4 dipeptidase inhibitor. Since the antibiotic, IMIPENEM, is hydrolyzed by dehydropeptidase-I, which resides in the brush border of the renal tubule, cilastatin is administered with imipenem to increase its effectiveness. The drug also inhibits the metabolism of leukotriene D4 to leukotriene E4. Cilastatin Monosodium Salt,Cilastatin Sodium,MK 0791,MK-791,MK0791,MK 791,MK791,Monosodium Salt, Cilastatin,Salt, Cilastatin Monosodium,Sodium, Cilastatin
D015378 Imipenem Semisynthetic thienamycin that has a wide spectrum of antibacterial activity against gram-negative and gram-positive aerobic and anaerobic bacteria, including many multiresistant strains. It is stable to beta-lactamases. Clinical studies have demonstrated high efficacy in the treatment of infections of various body systems. Its effectiveness is enhanced when it is administered in combination with CILASTATIN, a renal dipeptidase inhibitor. Imipemide,N-Formimidoylthienamycin,Imipenem Anhydrous,Imipenem, Anhydrous,MK-0787,MK0787,Anhydrous Imipenem,Anhydrous, Imipenem,MK 0787,N Formimidoylthienamycin

Related Publications

B Lipman, and H C Neu
December 1986, Minnesota medicine,
B Lipman, and H C Neu
January 1986, Giornale di batteriologia, virologia ed immunologia,
B Lipman, and H C Neu
December 1985, Drug intelligence & clinical pharmacy,
B Lipman, and H C Neu
September 1986, Clinical pharmacy,
B Lipman, and H C Neu
December 2010, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists,
B Lipman, and H C Neu
January 1997, Pharmacotherapy,
B Lipman, and H C Neu
July 1981, The Journal of antibiotics,
B Lipman, and H C Neu
May 1991, Drug and therapeutics bulletin,
B Lipman, and H C Neu
March 2021, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists,
Copied contents to your clipboard!